• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacology, Biochemistry and Behavior >Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes
【24h】

Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes

机译：大麻素诱导的1型和2型糖尿病大鼠神经性疼痛缓解的特征

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Diabetic neuropathy is a frequent complication of diabetes mellitus with a tremendous impact on patients' quality of life, and it remains poorly treated. Cannabinoids relieve the signs of diabetic neuropathy in different experimental models, including streptozotocin- (STZ-) induced type 1 diabetic rodents, and they may also relieve neuropathic signs in type 2 diabetic animals. This study compares the effect of the non-selective cannabinoid agonist WIN 55,212-2 (WIN) in Zucker Diabetic Fatty (ZDF) rats (type 2 diabetes) and in STZ-injected Wistar rats (type 1 diabetes). WIN (or its vehicle) was either systemically administered at a non-psychoactive dose or locally injected. Selective CB1 and CB2 cannabinoid antagonists were used to characterize WIN antineuropathic effects. Both type 1 and type 2 diabetic rats showed mechanical allodynia but not thermal hyperalgesia. WIN alleviated mechanical allodynia in both models of diabetes. In STZ-treated rats, both cannabinoid receptors were involved, whereas in ZDF rats, WIN effects seemed to mainly involve the activation of CB1 receptors. Higher doses of WIN were needed to significantly relieve mechanical allodynia upon intraplantar administration in ZDF vs. STZ-injected rats. Cannabinoids, acting on systemic and/or peripheral receptors, may serve as a new therapeutic alternative for symptom management in painful neuropathy associated with both type 1 and type 2 diabetes. Additionally, our results highlight the need for appropriate selection of diabetic experimental models because the results from studies in STZ-induced diabetic rodents might not be applicable in all diabetic situations.
机译：糖尿病性神经病是糖尿病的一种常见并发症，对患者的生活质量产生巨大影响，并且仍然受到不良治疗。大麻素在不同的实验模型（包括链脲佐菌素（STZ-）诱导的1型糖尿病啮齿动物）中缓解了糖尿病性神经病的体征，并且还可以缓解2型糖尿病动物的神经性体征。这项研究比较了非选择性大麻素激动剂WIN 55,212-2（WIN）对Zucker糖尿病脂肪（ZDF）大鼠（2型糖尿病）和注射STZ的Wistar大鼠（1型糖尿病）的作用。 WIN（或它的媒介物）以非精神活性剂量全身给药或局部注射。选择性CB1和CB2大麻素拮抗剂用于表征WIN抗神经病理作用。 1型和2型糖尿病大鼠均显示出机械性异常性疼痛，但未出现热痛觉过敏。 WIN减轻了两种糖尿病模型的机械性异常性疼痛。在STZ处理的大鼠中，两种大麻素受体均参与，而在ZDF大鼠中，WIN效应似乎主要涉及CB1受体的激活。与注射STZ的大鼠相比，在ZDF足底给药后，需要更高剂量的WIN才能显着缓解机械异常性疼痛。作用于全身和/或外周受体的大麻素可作为与1型和2型糖尿病相关的疼痛性神经病的症状管理的新治疗替代品。此外，我们的结果强调需要适当选择糖尿病实验模型，因为STZ诱导的糖尿病啮齿动物的研究结果可能不适用于所有糖尿病情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号